TENSIVE 

CONTROLS, INC

Reach us at
(573) 881-5080

Intellectual Property

One issued patent and four pending patents protect our technology platform.

NCI/NIH Grant Support

The National Cancer Institute continues to fund our underpinning research in cancer cachexia.

4

2

1

Tensive Controls technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.



Tensive Controls Angiotensin (1-7) analog anti-tumor agent has been licensed and is in pre-clinical development.  Our cancer cachexia drug candidate is completing pre-clinical development.  Discovery programs are in progress with antimicrobial, anti-biofilm and antiviral peptides. 

MAJOR MILESTONES

Tensive Controls' lead drug candidate is a peptide therapeutic for cancer cachexia.


The company  was formed in 2009 to understand why melanocortin-based peptide drug candidates exhibit adverse cardiovascular side effects and to synthesize analogs free of such side effects as potential drug therapies. 



PIPELINE

TECHNOLOGY

WELCOME

3

Investment

The company recently closed on a Series A financing.

Subsidiary Formed

We established Animal Health Specialties LLC to commercialize our technology platform for applications in veterinary medicine and animal production.

Tensive Controls Cancer Cachexia Peptide platform